The early noughties - Treating to Target

Holman RR, for the UKPDS Group. A brief history of the UK Prospective Diabetes Study. Br J Diabetes 2022;22(Supp1):S31-S34. https://doi.org/ 10.15277/bjd.2022.359

Yki-Järvinen H, Hanninen J, Hulme S, et al. Treat To Target Simply - the LANMET Study. Diabetes 2004;53(suppl 2). Abstract 2181-PO.

Yki-Järvinen H, Haring H, Zeger S, et al. The relationship between HbA1c, fasting blood glucose (FBG), and hypoglycaemia using insulin glargine ver- sus NPH insulin: a meta-regression analysis in type 2 diabetes (Abstract). Diabetes 2003;52(Suppl 1):A149.

Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin reg- imens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389–96. https://doi.org/10.7326/0003- 4819-130-5-199003020-00002

Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regi- mens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327(20):1426-33. https://doi.org/10.1056/nejm199211123272005

Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long- acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23(5):644-9. https://doi.org/10.2337/diacare.23.5.644

Riddle M, Rosenstock J. Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy. Diabetologia August 2002; 45(Suppl 2): A52; Abstract 150.

Rosenstock J, Riddle M. Treatment to target in Type 2 diabetes: consistent risk reduction of hypoglycaemia with basal insulin glargine as compared with NPH insulin in insulin-naïve patients on oral agents. Diabetologia Au- gust 2002;45(Suppl 2):A259; Abstract 805.

Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: random- ized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080-6. https://doi.org/ 10.2337/diacare.26.11.3080

Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49(3):442-51. https://doi.org/10.1007/s00125-005-0132-0

Davies M, Lavalle-González F, Storms F, et al. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidi- abetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 2008;10(5):387-99. https://doi.org/10.1111/j.1463-1326.2008.00873.x

Ryder REJ, Cutler J, Cull ML, Mills AP. The effect of a “Treat to Target” ap- proach with insulin glargine in patients with persistent poor glycaemic con- trol on traditional treatment with twice daily insulin mixtures. Practical Diabetes Int 2007;24(2):111.

Ryder REJ, Cutler J, Cull ML, Mills AP. Application of a “Treat to Target” approach with once daily long acting insulin at bedtime in the “real world” of unselected patients in an inner city area. Practical Diabetes Int 2007; 24(2):111.

All ABCD Audit Publications. See: https://abcd.care/all-abcd-audit-publi- cations (accessed 8 November 2022).

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65(12):1925-66. https://doi.org/10.1007/ s00125-022-05787-2

Battelino T, Danne T, Edelman SV, et al. CGM-based Time-in-Range Using Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Type 1 Diabetes: The Head-to-Head Randomized Controlled InRange Trial. Diabetes Obes Metab 2022 Oct 20. Online ahead of print. https://doi.org/10.1111/dom.14898